Marksans Pharma Ltd
Q1 FY27, unaudited
- Revenue
- ₹321.19 Cr
- Profit after tax
- ₹69.04 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 321.19 | +0.45% | 1,341.48 |
| Other income | 17.47 | +769.15% | 103.53 |
| Total income | 338.66 | +5.26% | 1,445.01 |
| Employee benefit expense | 31.78 | +13.87% | 121.98 |
| Finance costs | 0.34 | +12.58% | 1.33 |
| Depreciation & amortisation | 8.78 | +7.18% | 34.23 |
| Total expenses | 248.20 | −3.86% | 1,053.47 |
| Profit before tax | 90.46 | +42.29% | 391.54 |
| Tax expense | 21.42 | +38.04% | 90.85 |
| Profit after tax | 69.04 | +43.66% | 300.70 |
| Total comprehensive income | 69.30 | +44.43% | 301.74 |
| Earnings per share, basic | ₹1.52 | ₹6.64 |
|---|---|---|
| Earnings per share, diluted | ₹1.52 | ₹6.63 |
Earnings call
Q4 FY26Marksans Pharma reported Q4 FY26 operating revenue of Rs 856 crores, up 20.8% year-on-year, with EBITDA margin expanding to 22.8% and profit after tax rising 64.3% to Rs 149 crores. For the full year, revenue crossed Rs 3,000 crores for the first time, reaching Rs 2,951 crores, with EBITDA margin at 20.4% and a year-end cash balance of Rs 990 crores. Management discussed raw material cost inflation linked to petroleum-related inputs and geopolitical disruption, alongside growth across North America, U.K., and Australia markets and new market entries in Germany, Canada and Ireland.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Filings
12 shown · 46 published by the exchange
20 Aug 2026
Transcript13 Aug 2026
13 Aug 2026
Filing12 Aug 2026
12 Aug 2026
Presentation12 Aug 2026
12 Aug 2026
06 Aug 2026
Filing04 Aug 2026
04 Aug 2026
04 Aug 2026
03 Aug 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 20 Aug 2026.